PK/PD for prevention of resistance: clinical data
Infect Control Hosp Epidemiol 2000 Jan;21(1 Suppl):S9-11 … / ... Four significantly differing patient groups were identified:
- group 1, P aeruginosa isolates from all sites other than the respiratory tract, treated with any drugs;
- group 2, respiratory tract isolates treated with drugs other than ciprofloxacin;
- group 3, respiratory tract isolates treated with ciprofloxacin at AUIC24 (microg x h/mL)/microg/mL;
- and group 4, respiratory tract isolates treated with ciprofloxacin at AUIC24 < or =110 (microg x h/mL)/microg/mL